Our analysis suggests that undergoing both RRSO and RRM is the most effective and cost-effective option for BRCA1, BRCA2, and PALB2 PV carriers, with younger surgery ages for those with higher cancer risk preventing more cancers. This evidence concerns the gene BRCA1 and cancer.